1. Home
  2. Events
  3. On Demand: The Use of Human iPSC-Derived Cells in Disease Modeling

On Demand: The Use of Human iPSC-Derived Cells in Disease Modeling

Axol Team

Access our presentation now

Our Scientific Support Manager, Dr Steven Broadbent, presented at the recent inaugural Innovations in Disease Modeling Virtual Event.

You can access the recording of his talk below

In his talk, Steven discussed how advances in human induced pluripotent stem cell (iPSC) technology enable the study of human disease phenotypes that are challenging to reproduce in animal models. Meaning, human iPSCs provide an attractive option for human disease modeling, drug screening, personalized medicine, cell-based therapy, and toxicity studies.

Specifically, Steven focussed on co-culture models, and how these provide a more physiologically relevant scenario by incorporating donor-matched cell-types or one or more disease lines. Co-culture models facilitate investigation of the individual and combined contribution of each cell type in models incorporating actual human cells differentiated into cell-types akin to those found in vivo. This level of refinement, control and human-relevance is often not possible at scale with existing animal, donor and heterologous cell models.

Watch Steven’s talk to understand:

  • The development of co-culture human iPSC disease models
  • Co-culture disease models and their relevance in drug screening

Press enquiries

Dr. Adam Tozer

Axol Bioscience

T: +44 (0) 7398 017191

E: adam.tozer@axolbio.com

W: axolbio.com

NOTES TO EDITOR

About Axol Bioscience

Axol is a leading provider of product and service solutions in the iPSC-based neuroscience, immune cell, and cardiac modeling for drug discovery and screening markets. Our custom research capabilities in gene editing, electrophysiology, reprogramming, and differentiation means we can offer customers validated ready-to-use cell lines and a suite of services bolstered by deep scientific expertise and robust functional data – all with shorter lead times. To find out more, visit axolbio.com.

Share this post:

Previous
ISSCR 2022: How do you SCIENCE?
Next
On-Demand Webinar: “CiPA Validation of hiPSC-Derived Cardiomyocytes for Drug Safety Evaluation” – June 9th